<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340622</url>
  </required_header>
  <id_info>
    <org_study_id>R43DA050358</org_study_id>
    <secondary_id>1R43DA050358-01</secondary_id>
    <nct_id>NCT04340622</nct_id>
  </id_info>
  <brief_title>Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders</brief_title>
  <official_title>A Project to Test The Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MindLight, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>MindLight, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will test, for safety and efficacy, a novel treatment for opiate addiction that
      applies a 4-minute treatment of intense near infra-red light to stimulate a side of the brain
      that the investigators determine to be healthier, more mature, and less traumatized.
      Investigators will compare an active and a sham treatment given twice weekly for 4-weeks.
      Investigators hope this will lead to a significant weapon in the battle against the opioid
      epidemic as well as lead to psychological and physiological insights into possible relations
      among trauma, cerebral laterality, and addiction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is to demonstrate that a novel treatment for opiate addiction is safe and far
      superior to a sham comparison treatment. The treatment is hoped to significantly aid in the
      battle against the opioid epidemic that is ravaging much of the country and the world. The
      treatment consists of using a 4-minute application of transcranial photobiomodulation, near
      infra-red mode, through a supra-luminous LED, to one side of the forehead over the brain
      hemisphere that we determine (through a proprietary test) to have a more positive emotional
      valence. Based on preliminary data, we anticipate that the treatment will be very effective
      in reducing drug cravings, anxiety, and depression as well as in reducing relapses. Aim I
      will offer twice-weekly treatments to two groups, active and sham, for 4-weeks and will look
      specifically for differences in opioid cravings, anxiety, depression, and opioid use. The
      investigators will evaluate participants weekly for safety and efficacy for 3-weeks
      post-treatment. In Aim II a highly-regarded product engineer will work with the company to
      design a marketable product that may have patentable elements.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>20 participants will receive twice a week active treatment for 4-weeks of a 4-minute near-infrared light treatment through the forehead to a brain hemisphere and 20 will receive a sham treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The sham is created by putting a piece of aluminum foil over the light-emitting diode. It will be placed there or not placed there by a 3rd party so that neither the participant nor the outcomes assessor will know the condition of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Opioid Craving Scale</measure>
    <time_frame>One year</time_frame>
    <description>a published 3 question scale of opioid cravings. Each question asks the patient to rate his opioid cravings at the present time from 0 (none) to 9 (extreme). We use the average of the scores of the 3 questions. A low score is best.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Opioid drug use</measure>
    <time_frame>One year</time_frame>
    <description>TimeLine FollowBack method, measures the daily amount of opioid drug use (mg's of pills or grams used) for the period between observations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patient reports of opioid use by TimeLine FollowBack method</measure>
    <time_frame>One year</time_frame>
    <description>patient reports supported by urine drug screens and a drug hair test at the end of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Opioid-use Disorder</condition>
  <condition>Opioid Dependence</condition>
  <condition>Opioid Abuse</condition>
  <arm_group>
    <arm_group_label>Reduction in opioid cravings and use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These participants will receive twice-weekly transcranial photobiomodulation with and 810 nm LED for 4 min for a delivery to the brain of 2.1 J/cm2. The treatment will last 4 weeks. We anticipate a 60% reduction in opioid cravings in this group. We anticipate a reduction of at least 1.6 days of use per week on average.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Small reduction in opioid cravings and use</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>supra-luminous LED</intervention_name>
    <description>810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.</description>
    <arm_group_label>Reduction in opioid cravings and use</arm_group_label>
    <other_name>unilateral trancranial photobiomodulation, near-infrared mode</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Light-emitting diode covered with aluminium foil</description>
    <arm_group_label>Small reduction in opioid cravings and use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients must between the ages of 18 and 70

          -  meet criterion for a history of Opioid Use Disorder (OUD) on a Diagnostic Interview.

          -  have opioid cravings

          -  Enrollment will be made without regard to gender or ethnicity.

          -  Patients who are receiving treatment for OUD or other psychiatric disorders, either
             psychological or pharmacological treatments, may continue their treatment during the
             time of the study but will be asked to try not to alter their treatment from the onset
             of the experiment until its conclusion. The statistical analysis will include
             covariates for doses of buprenorphine and methadone and use of non-prescribed opioids

        Exclusion Criteria:

          -  past history of a psychotic disorder (including schizophrenia or schizoaffective
             disorder)

          -  history of violent behavior

          -  history of a past suicide gesture or attempt, a history of current suicidal ideation,
             *history of a neurological condition (e.g. epilepsy, traumatic brain injury, stroke),
             *pregnancy

          -  current acute or chronic medical condition requiring a medication that has
             psychological side-effects.

          -  impaired decision-making capacity in the judgment of the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredric Schiffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MindLight, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Teicher, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McLean Hospital and Harvard Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fredric Schiffer, MD</last_name>
    <phone>781-405-8800</phone>
    <email>fschiffer1@verizon.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Al Khan, MD</last_name>
    <phone>617-855-2970</phone>
    <email>akhan@mclean.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Al Khan, MD</last_name>
      <phone>617-855-2970</phone>
      <email>akhan@mclean.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Martin Teicher, MD, PhD</last_name>
      <phone>617-855-2970</phone>
      <email>martin_teicher@hms.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MindLight, LLC</name>
      <address>
        <city>Newton Highlands</city>
        <state>Massachusetts</state>
        <zip>02461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredric Schiffer, MD</last_name>
      <phone>781-405-8800</phone>
      <email>fschiffer1@verizon.net</email>
    </contact>
    <contact_backup>
      <last_name>Edward Flynn</last_name>
      <phone>â€­(617) 424-0665</phone>
      <email>flynn.ted@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Without any identifying participant information, study data may be shared at the investigator's discretion.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>upon completion of the study</ipd_time_frame>
    <ipd_access_criteria>Investigators will not share any individual participant identifying data. Each participant will be given a participant number and this number will be shared with the participant's data. All participant data will be shared but without any participant, personal identifying data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

